Highlights1
DSM delivered a good first quarter
Group sales +18% and Adjusted EBITDA +10%
Health, Nutrition & Bioscience: Sales +16%, organic sales +9%, Adjusted EBITDA +9%
Materials: Sales +25%, organic sales +21%, Adjusted EBITDA +11%
Full Year outlook 2022 unchanged
Key figures2
in € million Q1 2022 Q1 2021 % Change Volume Price/mix FX Other
Sales 2,590 2,194 18% 2% 10% 5% 1%
HNB 1,987 1,711 16% 3% 6% 5% 2%
ANH 881 778 13% -3% 11% 5% 0%
HNC 726 625 16% 8% 3% 5% 0%
F&B 362 296 22% 7% 3% 3% 9%
Materials 582 467 25% -4% 25% 4% 0%
Adjusted EBITDA 487 441 10%
HNB 391 359 9%
Materials 120 108 11%
Corporate -24 -26
EBITDA 466 425
Adjusted EBITDA margin 18.8% 20,1%
Co-CEO statement
Geraldine Matchett and Dimitri de Vreeze, Co-CEOs, commented: “DSM had a good start to the year with robust demand across our businesses and effective pricing measures to counteract inflation throughout the value chain. Despite the ongoing global logistics and supply chain challenges, the excellence of our people and our operations ensured we were able to continue to satisfy our customers’ needs. While we see ongoing volatility, resilient demand for our innovative and sustainability-focused solutions, together with our ability to drive effective pricing, leads us to reiterate our full year outlook.”

Outlook 2022
DSM’s outlook for the full year is unchanged. DSM expects its Health, Nutrition & Bioscience activities to deliver a high-single digit Adjusted EBITDA increase. For the Group, it expects a mid-single digit Adjusted EBITDA increase, with a high-single Adjusted Net Operating Free Cash Flow increase. This outlook is based on DSM’s expectation of a stable Adjusted EBITDA in Materials following the strong performance in 2021.

The complete version of this press release can be found here.

1 Adjusted EBITDA is an Alternative Performance Measure (APM) that reflects results from usual operations. Organic sales growth is the total impact of volume and price/mix. Adjusted Net Operating Free Cash Flow is the cash flow from operating activities, corrected for the cash flow of the APM adjustments, minus the cash flow of capital expenditures and drawing rights.

2 DSM’s Health, Nutrition & Bioscience structure became effective as of 1 January 2022. It consists of three businesses: Animal Nutrition and Health (ANH), Health, Nutrition and Care (HNC) and Food & Beverage (F&B). The preliminary comparative financial figures for 2021 were released in April 2022.

see & read more on
https://www.dsm.com/corporate/news/news-archive/2022/q1-2022-trading-update.html


DSM - repurchase of shares (25-29 April 2022)
Heerlen, NL, 03 May 2022 08:00 CET

Royal DSM, a global purpose-led science-based company, has repurchased 157,671 of its own shares in the period from 25 April 2022 up to and including 29 April 2022 at an average price of €156.34. This is in accordance with the repurchase program announced on 10 March 2022, covering the commitments for the final stock dividend 2021 and share based compensation plans. The consideration of this repurchase was €24.7 million.

The total number of shares repurchased under this program since 10 March 2022 to date is 1,289,915 shares for a total consideration of €204 million.

For more detailed information see Daily transaction details Share Repurchase Program announced 10 March 2022.

tijd 10.27
DSM EUR 151.95 -3,65 vol. 112.699